Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica.

1994151 citationsJournal Articlebronze Open Access

Authors

Trapidil reduces restenosis after PTCA at the dosage of 100 mg TID and favorably influences the clinical outcome thereafter.

Good health and well-being

Published in: Circulation

Volume 90, Issue 6, pp. 2710-2715

Field-Weighted Citation Impact: 9.23